The stock market is down Friday, with the Dow Jones Industrial Average down 0.01%, the Nasdaq down 0.51% and the S&P 500 down 0.27%. Today’s winners include a technology company which has secured financing for a restructuring and a pharmaceutical company whose drug has received positive remarks from European regulators. Today’s losers include a retailer whose ownership remains in limbo and another pharmaceutical company who is selling stock.
These are Friday’s market winners and losers.
Biggest Winners
Shares of Alcatel-Lucent, S.A. (NYSE: ALU) is up 10.29% to $1.21 on trading volume of 9.9 million shares. The firm has secured $2.1 billion in financing for a restructuring plan. The 52-week high is $2.66.
Shares of Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) are up 8.57% to $5.69 on trading volume of 1.9 million shares. European regulators have called for the approval of experimental drug Adasuve, which helps with schizophrenia and bipolar disorder. The 52-week high is $9.90.
Biggest Losers
Shares of Best Buy Co. Inc. (NYSE: BBY) are down 15.01% to $12.00 on trading volume of 19.1 million shares. The company has extended the deadline for founder Richard Schulze to make a bid for the company to Feb. 28. The 52-week low is $11.28.
Shares of Cytori Therapeutics, Inc. (NASDAQ: CYTX) are down 14.76% to $2.83 on trading volume of 2.4 million shares. The company said it will sell 7 million shares of stock at $2.85 a share. The 52-week low is $1.90.
Samuel Weigley
Follow him on Twitter: SWeigley
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.